BACKGROUND: Antiviral resistance among influenza A viruses is associated with high morbidity and mortality in immunocompromised hosts. However, treatment strategies for drug-resistant influenza A are not established. A triple-combination antiviral drug (TCAD) regimen consisting of amantadine (AMT), oseltamivir (OSL) and ribavirin (RBV) demonstrated good efficacy in an animal model. METHODS: We first analysed the pharmacokinetics (PKs) of TCAD therapy in healthy volunteers. We then performed a pilot study of TCAD therapy in patients undergoing chemotherapy or haematopoietic cell transplantation. AMT (75 mg), OSL (50 mg) and RBV (200 mg) were administered three times a day for 10 days. The safety and PKs of TCAD therapy were monitored. RESULTS: The PKs of TCAD therapy in healthy volunteers was shown to be similar to the PKs of each drug individually from a single dose. In the pilot study, six immunocompromised patients received TCAD therapy and one patient received OSL monotherapy. All but one patient completed 10 days of TCAD therapy without side effects; one patient receiving TCAD was withdrawn from the study because of respiratory failure and ultimately recovered. Viral load was decreased after TCAD therapy, despite the presence of either AMT- or OSL-resistant virus in two cases. One patient with 2009 influenza A/H1N1 receiving OSL monotherapy developed confirmed OSL resistance during treatment. CONCLUSIONS: TCAD therapy had similar PKs to each individual antiviral during monotherapy following a single dose and can be administered safely in immunocompromised patients.
BACKGROUND: Antiviral resistance among influenza A viruses is associated with high morbidity and mortality in immunocompromised hosts. However, treatment strategies for drug-resistant influenza A are not established. A triple-combination antiviral drug (TCAD) regimen consisting of amantadine (AMT), oseltamivir (OSL) and ribavirin (RBV) demonstrated good efficacy in an animal model. METHODS: We first analysed the pharmacokinetics (PKs) of TCAD therapy in healthy volunteers. We then performed a pilot study of TCAD therapy in patients undergoing chemotherapy or haematopoietic cell transplantation. AMT (75 mg), OSL (50 mg) and RBV (200 mg) were administered three times a day for 10 days. The safety and PKs of TCAD therapy were monitored. RESULTS: The PKs of TCAD therapy in healthy volunteers was shown to be similar to the PKs of each drug individually from a single dose. In the pilot study, six immunocompromised patients received TCAD therapy and one patient received OSL monotherapy. All but one patient completed 10 days of TCAD therapy without side effects; one patient receiving TCAD was withdrawn from the study because of respiratory failure and ultimately recovered. Viral load was decreased after TCAD therapy, despite the presence of either AMT- or OSL-resistant virus in two cases. One patient with 2009 influenzaA/H1N1 receiving OSL monotherapy developed confirmed OSL resistance during treatment. CONCLUSIONS:TCAD therapy had similar PKs to each individual antiviral during monotherapy following a single dose and can be administered safely in immunocompromised patients.
Authors: Aeron C Hurt; Tawee Chotpitayasunondh; Nancy J Cox; Rod Daniels; Alicia M Fry; Larisa V Gubareva; Frederick G Hayden; David S Hui; Olav Hungnes; Angie Lackenby; Wilina Lim; Adam Meijer; Charles Penn; Masato Tashiro; Timothy M Uyeki; Maria Zambon Journal: Lancet Infect Dis Date: 2011-12-18 Impact factor: 25.071
Authors: Won-Young Kim; Gee Young Suh; Jin Won Huh; Sung-Han Kim; Min-ju Kim; Yun Seong Kim; Hye-Ryoun Kim; Yon Ju Ryu; Min Soo Han; Young Gwan Ko; Gyu Rak Chon; Kwan Ho Lee; Sang-Ho Choi; Sang-Bum Hong Journal: Antimicrob Agents Chemother Date: 2011-10-03 Impact factor: 5.191
Authors: Dat Tran; Michelle Science; David Dix; Carol Portwine; Shayna Zelcer; Donna L Johnston; Rochelle Yanofsky; Adam Gassas; Marie-Chantal Ethier; Lillian Sung Journal: Influenza Other Respir Viruses Date: 2012-03-14 Impact factor: 4.380
Authors: J J Treanor; F G Hayden; P S Vrooman; R Barbarash; R Bettis; D Riff; S Singh; N Kinnersley; P Ward; R G Mills Journal: JAMA Date: 2000-02-23 Impact factor: 56.272
Authors: K G Nicholson; F Y Aoki; A D Osterhaus; S Trottier; O Carewicz; C H Mercier; A Rode; N Kinnersley; P Ward Journal: Lancet Date: 2000-05-27 Impact factor: 79.321
Authors: Justin D Hoopes; Elizabeth M Driebe; Erin Kelley; David M Engelthaler; Paul S Keim; Alan S Perelson; Libin Rong; Gregory T Went; Jack T Nguyen Journal: PLoS One Date: 2011-12-29 Impact factor: 3.240
Authors: Aaron D Storms; Larisa V Gubareva; Su Su; John T Wheeling; Margaret Okomo-Adhiambo; Chao-Yang Pan; Erik Reisdorf; Kirsten St George; Robert Myers; Jason T Wotton; Sara Robinson; Brandon Leader; Martha Thompson; Marjorie Shannon; Alexander Klimov; Alicia M Fry Journal: Emerg Infect Dis Date: 2012-02 Impact factor: 6.883
Authors: Simone E Adams; Vladimir Y Lugovtsev; Anastasia Kan; Nicolai V Bovin; Raymond P Donnelly; Natalia A Ilyushina Journal: Antimicrob Agents Chemother Date: 2020-06-23 Impact factor: 5.191
Authors: Wouter J Meijer; Wiete Kromdijk; Marcel P H van den Broek; Pieter-Jan A Haas; Monique C Minnema; Charles A Boucher; Dylan W de Lange; Annemarie M J Wensing Journal: Case Rep Infect Dis Date: 2015-08-09